Contraindications: Decaver must not be used by individuals with androgen-sensitive prostate or breast pathology, active hepatic disease, hypercalcaemia, or known hypersensitivity to Nandrolone Decanoate or sesame/arachis oil excipients. Pregnancy and breastfeeding are absolute contraindications. Paediatric use is contraindicated due to premature epiphyseal closure risk.
Side_Effects: HPTA suppression is the primary PCT-relevant adverse effect; severity correlates with cycle duration and weekly dose. Prolactin elevation (unique to 19-nor compounds), fluid retention, lipid profile disruption (HDL reduction, LDL elevation), haematocrit increase, and injection-site reactions are all dose-dependent. Androgenic effects including acne and scalp thinning are lower in incidence than with testosterone but not absent.
Monitoring: Mandatory pre-cycle bloodwork: total testosterone, LH, FSH, prolactin, oestradiol, haematocrit, and a full lipid panel. Repeat mid-cycle at week 6–8. Obtain the PCT baseline panel during the clearance window (days 7–14 post-final-injection). Final recovery confirmation requires two sequential panels showing normalised LH, FSH, and testosterone without exogenous androgen support.
PCT: Post-Cycle Therapy after Decaver must not begin until 14–21 days after the final injection. The standard protocol is a SERM (Tamoxifen 20–40 mg/day or Clomiphene 50 mg/day) for 8–12 weeks. Elevated prolactin confirmed by bloodwork requires concurrent dopamine agonist therapy. Do not substitute AI (aromatase inhibitor) monotherapy for SERM-based PCT in Nandrolone recovery — the primary suppression mechanism is not oestrogen-mediated and AI alone will not restore LH/FSH output.